Fresenius Kabi announced today it has signed an agreement with Virginia Oncology Associates (VOA) under which VOA will purchase the Ivenix Infusion System to deliver medications for its patients.
Virginia Oncology Associates Chooses the Ivenix Infusion System from Fresenius Kabi Read More »
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for INGREZZA ® (valbenazine) oral granules, a new sprinkle formulation of INGREZZA.
Today, Mayo Clinic and GE HealthCare announce a strategic healthcare collaboration for research and product development programs aimed to transform the experience of patients and clinicians in the practice of radiology and the delivery of novel therapies.
La tecnología está demostrando ser una fuerza poderosa para crear inclusión y superar los desafíos que enfrentan las personas con discapacidad. Conozcamos algunas de las herramientas tecnológicas más innovadoras que están cambiando vidas y derribando …
Herramientas innovadoras para superar la discapacidad Read More »
NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced it will host its fifth annual Spatial Genomics Summit, September 19th.
NanoString to Host Virtual Spatial Genomics Summit September 19, 2023 Read More »
Evecxia Therapeutics, Inc., the leader in serotonin synthesis amplification to treat brain disorders, today announced that Dr. Jacob Jacobsen has been appointed President and CEO.
Biophytis SA today announced the strengthening of its management team with the appointment of Edouard Bieth as Chief Business Officer and member of the Executive Committee.
Dizal today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for golidocitinib for the treatment of relapsed or refractory peripheral T-cell lymphoma (r/r PTCL).
Medivir AB announces that the company will present at the Pareto Securities Healthcare Conference.
Medivir to present at the Pareto Securities Healthcare Conference – September 14, 2023 Read More »
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, said on Thursday it is well on track to achieve its 2030 emission reduction targets, and that it had received approval of those targets from the Science Based Targets initiative.
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets Read More »
